The Project Development of an innovative nanotechnology strategy to combat potentially counterfeit drugs The pharmaceutical industry impacts countless lives around the world by researching and developing lifesaving and life-enhancing products. Operating sustainably is reflected in a commitment to supply high-quality and safe products, while developing new and improved therapies to address unmet medical needs.  In this context, project aims to design anti-counterfeit sustainable strategies based on nanotechnology, to combat this global threat to public health and help ensure the integrity of original products.  The project aims to develop a range of nanometric based polymer neutral powders for the invisible marking of drug products. This technology will be designed to counter the problem of counterfeiting. The obtained markers aim to emit colour when illuminated with a specific type of ultraviolet light. This marking process is guaranteed indelible, difficult to copy or alter and has no effects in any way. The project will contribute to the progress of scientific knowledge by advanced research for solving a complex health problem and developing original solutions in the area of Counterfeit Medicine.  ADDED VALUE in terms of expertise development of early participating researchers: Publish high quality research papers; Gain a relevant and improved understanding of clinical requirements in the field of counterfeit medicine based on process design strategies. The proposed project ensures sharing of the biomimetic chemical, in vitroand in vivomodels and informatics databases, but also access to the available infrastructures of all parties according to collaboration agreements.  What do we need?  Private Partner in a project proposal that will be submitted to H2020 Programme, Marie Skłodowska-Curie Actions - Innovative Training Networks (ITN) type ETN, Call 2019 for hosting, training and seconding early stage researchers.  Partner Organisations contribute to the implementation of the action, but do not sign the Grant Agreement. They provide additional research and transferable skills training and/or secondment opportunities. Secondment: is a period of research training with another beneficiary, its entities with a capital or legal link, or a partner organisation implemented to further enrich the training experience of a researcher. The total secondment duration to partner organisations (irrespective of the sector) is limited to a maximum of 30% of the fellowship duration (max. 9 months over a period of 36 months). Partner organisations cannot directly claim any costs. Instead, the costs they incur for activities in the research training programme are to be covered by the unit costs paid to the beneficiaries. To sum up, Grigore T Popa University of Medicine and Pharmacy (Iasi, Romania) is looking for a company, ideally from the pharma industry, that will be able to host 2 phd students, foreign but enrolled for the programme in Romania, for 9 months. The phd students will be granted scholarships by the university and any other costs might be covered by the programme.   Due the fact that the deadline is short, please get in contact with us as soon as possible if any of your stakeholders are interested: Bogdan Chelariu, Head of Brussels Office, ADR Nord-Est, bogdan@adrnordest.ro and Gianina Dodi, PhD, Medical Bioengineer, Research scientist, UMF Iasi, M +40-740 087 013, gianina.dodi@yahoo.co.uk .